PubRank

Robert R Redfield

Author PubWeight™ 59.27‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Impact of persistent HIV replication on CD4 negative Vγ2Vδ2 T cells. J Infect Dis 2012 1.70
2 Improved renal ischemia tolerance in females influences kidney transplantation outcomes. J Clin Invest 2016 1.51
3 When Do DCD Donors Die?: Outcomes and Implications of DCD at a High-volume, Single-center OPO in the United States. Ann Surg 2016 1.42
4 Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection. Lancet Infect Dis 2008 1.42
5 Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc Natl Acad Sci U S A 2009 1.41
6 HIV-1 natural viral suppressors: control of viral replication in the absence of therapy. AIDS 2007 1.38
7 Epidemiologic characteristics and natural history of HIV-1 natural viral suppressors. J Acquir Immune Defic Syndr 2009 1.34
8 CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1. AIDS 2007 1.23
9 Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J Infect Dis 2008 1.22
10 Clinical use of CCR5 inhibitors in HIV and beyond. J Transl Med 2011 1.15
11 Hepatitis C infection in HIV-1 natural viral suppressors. AIDS 2010 1.13
12 Association between longer duration of HIV-suppressive therapy and partial recovery of the V gamma 2 T cell receptor repertoire. J Infect Dis 2004 1.10
13 Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proc Natl Acad Sci U S A 2008 1.09
14 Natural viral suppressors of HIV-1 have a unique capacity to maintain gammadelta T cells. AIDS 2009 1.05
15 Chronic immune activation and decreased CD4 cell counts associated with hepatitis C infection in HIV-1 natural viral suppressors. AIDS 2012 1.02
16 High cancer-related mortality in an urban, predominantly African-American, HIV-infected population. AIDS 2013 0.99
17 Treatment outcomes of recommended first-line antiretroviral regimens in resource-limited clinics. J Acquir Immune Defic Syndr 2012 0.98
18 Indirubin-3'-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication. AIDS 2005 0.96
19 A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir Ther 2006 0.93
20 Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: lessons learned. J Acquir Immune Defic Syndr 2005 0.93
21 Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment. AIDS 2007 0.92
22 Role of secondary level laboratories in strengthening quality at primary level health facilities' laboratories: an innovative approach to ensure accurate HIV, tuberculosis, and malaria test results in resource-limited settings. Diagn Microbiol Infect Dis 2012 0.90
23 Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother 2007 0.89
24 Soluble factors from T cells inhibiting X4 strains of HIV are a mixture of β chemokines and RNases. Proc Natl Acad Sci U S A 2012 0.88
25 Elevated hypermutation levels in HIV-1 natural viral suppressors. Virology 2013 0.88
26 Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity. J Acquir Immune Defic Syndr 2011 0.88
27 CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells. Virology 2011 0.86
28 Murine islet allograft tolerance upon blockade of the B-lymphocyte stimulator, BLyS/BAFF. Transplantation 2012 0.86
29 Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263). AIDS Res Hum Retroviruses 2009 0.86
30 Targeting γδ T cells for immunotherapy of HIV disease. Future Virol 2011 0.86
31 Induction of G1 cycle arrest in T lymphocytes results in increased extracellular levels of beta-chemokines: a strategy to inhibit R5 HIV-1. Proc Natl Acad Sci U S A 2003 0.86
32 Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine. Clin Infect Dis 2008 0.84
33 Acquisition of humoral transplantation tolerance upon de novo emergence of B lymphocytes. J Immunol 2010 0.83
34 Impact of horizontal approach in vertical program: continuous quality improvement of malaria and tuberculosis diagnostic services at primary-level medical laboratories in the context of HIV care and treatment program in Ethiopia. Am J Trop Med Hyg 2013 0.82
35 Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat protein. J Virol 2004 0.82
36 Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort. J Infect Dis 2004 0.82
37 IL28B genotype does not correlate with HIV control in African Americans. Clin Transl Sci 2011 0.82
38 Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients. AIDS Patient Care STDS 2006 0.81
39 Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma. J Virol 2012 0.81
40 Targeting of the purine biosynthesis host cell pathway enhances the activity of tenofovir against sensitive and drug-resistant HIV-1. J Infect Dis 2013 0.80
41 B-cell tolerance in transplantation: is repertoire remodeling the answer? Expert Rev Clin Immunol 2009 0.80
42 Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists. Antiviral Res 2009 0.79
43 Indirubin 3'-monoxime, from a Chinese traditional herbal formula, suppresses viremia in humanized mice infected with multidrug-resistant HIV. AIDS Res Hum Retroviruses 2014 0.79
44 Influence of transportation cost on long-term retention in clinic for HIV patients in rural Haiti. J Acquir Immune Defic Syndr 2014 0.79
45 In vitro suppression of latent HIV-1 activation by vitamin E: potential clinical implications. AIDS 2005 0.79
46 B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation. Transplant Rev (Orlando) 2010 0.79
47 Acute renal failure and nephrotic range proteinuria due to amyloidosis in an HIV-infected patient. Am J Med Sci 2006 0.78
48 Impact of HIV on lung tumorigenesis in an animal model. AIDS 2015 0.78
49 The use of preexposure treatments for HIV prophylaxis. HIV AIDS (Auckl) 2012 0.78
50 Tenofovir and abacavir combination therapy: lessons learned from an urban clinic population. AIDS Patient Care STDS 2007 0.78
51 Improving on success: what treating the urban poor in America can teach us about improving antiretroviral programmes in Africa. AIDS 2004 0.78
52 Altered T-cell subsets in HIV-1 natural viral suppressors (elite controllers) with hepatitis C infection. AIDS 2013 0.78
53 Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1. AIDS 2014 0.78
54 Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention. AIDS 2011 0.78
55 Long-term nonprogressive disease among individuals with untreated HIV infection. JAMA 2010 0.77
56 HIV-associated lymphoma sub-type distribution, immunophenotypes and survival in an urban clinic population. Leuk Lymphoma 2015 0.77
57 Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment. Curr HIV Res 2016 0.76
58 Virtual HLA Crossmatching as a Means to Safely Expedite Transplantation of Imported Pancreata. Transplantation 2016 0.76
59 Therapeutic HIV vaccines. Curr Top Med Chem 2003 0.76
60 Calcineurin Inhibitor Minimization With Ixazomib, an Investigational Proteasome Inhibitor, for the Prevention of Antibody Mediated Rejection in a Preclinical Model. Transplantation 2015 0.76
61 Primary B cell repertoire remodeling to achieve humoral transplantation tolerance. Semin Immunol 2011 0.76
62 Commentary on "Prevalence and evolution of drug resistance HIV-1 variants in Henan, China". Cell Res 2005 0.75
63 Reply to Hartjen et al. J Infect Dis 2013 0.75
64 Progression of monoclonal gammopathy of undetermined significance to multiple myeloma in a solid organ transplant. Transplantation 2011 0.75
65 Strategies for B-lymphocyte repertoire remodeling in transplantation tolerance. Immunol Res 2011 0.75
66 The Importance and Utility of Hemoglobin A1c Levels in the Assessment of Donor Pancreas Allografts. Transplantation 2016 0.75
67 Long-term follow-up of elite controllers: Higher risk of complications with HCV coinfection, no association with HIV disease progression. Medicine (Baltimore) 2017 0.75
68 HIV drug resistance mutations among patients failing second-line antiretroviral therapy in Rwanda. Antivir Ther 2015 0.75
69 Viral load decay in antiretroviral-naïve patients receiving once-daily tenofovir and emtricitabine plus twice-daily nevirapine. HIV Clin Trials 2009 0.75
70 Approaches to antiretroviral therapy in China. Cell Res 2005 0.75
71 An Evaluation of the Safety and Efficacy of Simultaneous Bilateral Nephrectomy and Renal Transplantation for Polycystic Kidney Disease: A 20-Year Experience. Transplantation 2017 0.75
72 ß cell replacement therapy: the next 10 years. Transplantation 2017 0.75
73 Immunologic response to ART by age among treatment-naïve patients in sub-Saharan Africa. AIDS 2017 0.75